Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices

Vamsidhar Velcheti, Sheenu Chandwani, Xin Chen, M. Catherine Pietanza, Bilal Piperdi, Thomas Burke

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

To determine real-world outcomes with first-line pembrolizumab monotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor expression ≥50%. Methods: This retrospective study included adults with ECOG 0-1 initiating first-line pembrolizumab monotherapy on/after 24 October 2016 (EHR cohort) or from 1 December 2016 through 30 November 2017 (spotlight cohort) with ≥6-month follow-up. We estimated Kaplan-Meier overall survival (OS, both cohorts), and, for spotlight, real-world progression-free survival (rwPFS) by Kaplan-Meier and real-world tumor response (rwTR). Results: For 423 patients in the EHR cohort and 188 in spotlight, median OS was 18.9 months (95% CI: 14.9-25.5) and 19.1 months (12.6-not reached), respectively. For spotlight, median rwPFS was 6.8 months (5.3-8.1); rwTR of complete/partial response was 48% (41-56%). Conclusion: Observed OS, rwPFS and rwTR were consistent with clinical trial findings.

Original languageEnglish (US)
Pages (from-to)1541-1554
Number of pages14
JournalImmunotherapy
Volume11
Issue number18
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Keywords

  • PD-L1
  • antineoplastic agents
  • comparative effectiveness research
  • non-small-cell lung carcinoma
  • pembrolizumab
  • survival analysis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices'. Together they form a unique fingerprint.

  • Cite this